All results

11 results for tests

• ProACT Post-Approval Study

  The ProACT Post Approval Study is a 5-year prospective, open-label, multi-center study designed to evaluate the long-term incidence of urethral stricture and…

  Ages

  50 Years - N/A

  Sexes

  Male

• EMBARK

  The study will evaluate the safety and efficacy of gene transfer therapy in boys with DMD. It is a randomized, double-blind, placebo-controlled study. The…

  Ages

  4 Years - 7 Years

  Sexes

  Male

• Pfizer Early Stage GT

  The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm,…

  Ages

  2 Years - 3 Years

  Sexes

  Male

• Givinostat Long Term Study

  This is an open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD (Duchenne's muscular dystrophy) patients who have been…

  Ages

  7 Years - N/A

  Sexes

  Male

• 9001-303 (ENVISION)

  The study will evaluate the safety and efficacy of delandistrogene moxeparvovec gene transfer therapy in non-ambulatory and ambulatory males with DMD. This is…

  Ages

  N/A - N/A

  Sexes

  Male

• ANCHORS: UH3

  80 young adult men will complete an initial survey and receive 1 of 2 types of alcohol and sexual health education and information to encourage prevention of…

  Ages

  18 Years - 30 Years

  Sexes

  Male

• Edgewise-201 (CANYON)

  A study of EDG-5506 in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to…

  Ages

  12 Years - 50 Years

  Sexes

  Male

• Edgewise-210

  The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…

  Ages

  4 Years - 9 Years

  Sexes

  Male

• Magnetic resonance imaging and biomarkers for muscular dystrophy

  The purpose of this research study is to determine the potential of magnetic resonance imaging, spectroscopy, and whole body imaging to monitor disease…

  Ages

  5 Years - 62 Years

  Sexes

  Male

• Genomic-Risk Stratified Txs for Unfavorable Intermediate Risk Prostate Cancer (Guidance)

  This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk)…

  Ages

  18 Years - N/A

  Sexes

  Male